Watch PAVM. Know when insiders buy.
One email the day a filing lands. Free.
PAVM
PAVmed Inc.
3.88
−0.11 −2.71%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $31MP/E —DIV YIELD —FCF YIELD -25.08%REV TTM $112K −89.0%NET INCOME −$12.1M −116.6%NET CASH —52W 3.88 – 16.65SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $33K | +450.0% | -269.7% | −$7M | −$5.4M | — | -0.87 | −$2.7M | $13K | −$2.7M | Aug 13 |
| Q1 2026 · Mar 31 | $22K | +175.0% | -340.9% | −$8M | −$60K | −100.3% | -4.42 | −$2.6M | $22K | −$2.6M | May 14 |
| Q4 2025 · Dec 31derived | $52K | — | -63.5% | −$6.8M | −$1.3M | −188.3% | -5.52 | −$1.6M | $14K | −$1.6M | Mar 27 |
| Q3 2025 · Sep 30 | $5K | −99.5% | -1000.0% | −$4.8M | −$5.4M | −108.4% | -0.29 | −$896K | $3K | −$899K | Nov 12 |
| Q2 2025 · Jun 30 | $6K | −99.4% | -583.3% | −$4.7M | −$11.9M | — | -22.08 | −$1.2M | $8K | −$1.2M | Aug 13 |
| Q1 2025 · Mar 31 | $8K | −99.2% | -350.0% | −$5.4M | $19M | — | 10.10 | −$1.6M | $6K | −$1.6M | May 14 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$5.2M | $1.4M | — | 14.11 | $94K | $4K | $90K | Mar 27 |
| Q3 2024 · Sep 30 | $1M | +26.4% | -38.1% | −$11.6M | $64.4M | — | 1.44 | −$8.9M | $6K | −$8.9M | Nov 12 |
| Q2 2024 · Jun 30 | $1M | — | -66.6% | −$13.7M | −$10.8M | — | -1.19 | −$11.7M | $3K | −$11.7M | Aug 14 |
| Q1 2024 · Mar 31 | $1M | — | -74.4% | −$14M | −$15.2M | — | -2.62 | −$13.1M | $42K | −$13.2M | May 15 |
| Q4 2023 · Dec 31derived | $1.1M | — | -46.9% | −$16.4M | −$14M | — | -1.93 | −$11.9M | $183K | −$12.1M | Mar 24 |
| Q3 2023 · Sep 30 | $791K | — | -124.9% | −$15.5M | −$17.7M | — | -2.38 | −$11.1M | $18K | −$11.1M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $71K | -207.0% | −$21.8M | $401K | 564.8% | -5.63 | −$5.2M | $31K | −$5.2M | — | — |
| FY2024 · to Dec 31 | $3M | -61.3% | −$44.5M | $39.8M | 1326.4% | 14.90 | −$33.6M | $55K | −$33.6M | — | — |
| FY2023 · to Dec 31 | $2.5M | -156.8% | −$68.8M | −$64.2M | -2567.0% | -9.16 | −$52M | $242K | −$52.3M | — | — |
| FY2022 · to Dec 31 | $377K | -858.6% | −$91.1M | −$89M | -23602.9% | -15.03 | −$71M | $1.5M | −$72.5M | — | — |
| FY2021 · to Dec 31 | $500K | -17.0% | −$54.4M | −$50.3M | -10069.4% | -0.65 | −$40.6M | $1.5M | −$42.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$23.4M | −$34.3M | — | -0.72 | −$21.9M | $55K | −$22M | — | — |
Every number comes from PAVmed Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.